Novartis Kisqali gets European Commission nod in patients with HR+/HER2-early breast cancer at high risk of recurrence Ruchika Sharma28 Nov 2024 12:59 PM ISTBasel: Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI)...
CDSCO Panel Approves Novartis Protocol Amendment Proposal to study Ribociclib Dr. Divya Colin28 Oct 2024 5:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Novartis' Ribociclib named as Category 1 Preferred Adjuvant Treatment for Breast Cancer in NCCN Guidelines Farhat Nasim27 Oct 2024 10:15 AM ISTBasel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib...
USFDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer Ruchika Sharma18 Sept 2024 3:04 PM ISTBasel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase...
Novartis Gets CDSCO Panel Nod to Study anti-cancer drug Ribociclib Dr. Divya Colin21 April 2024 5:30 PM ISTNew Delhi: The drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence: NEJM Dr. Kamal Kant Kohli26 March 2024 11:15 PM ISTA new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2...
Roche Gets CDSCO Panel Nod to Study anti-cancer Drug Giredestrant for Breast Cancer Dr. Divya Colin7 Jan 2024 6:00 PM ISTNew Delhi: The drug major Roche has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
Novartis Kisqali significantly reduced risk of recurrence by 25% across broad population of patients with early breast cancer: Novartis Ruchika Sharma4 Jun 2023 1:00 PM ISTBasel: Novartis has presented positive primary endpoint data from the pivotal Phase III NATALEE trial at the 2023 American Society of Clinical...
Kerala HC directs Health Ministry, DoP to reply on unaffordability of patented cancer drug Ribociclib Roshni Dhar4 Oct 2022 4:49 PM ISTThe Kerala High Court has directed the Department of Pharmaceuticals (DoP) and a competent officer of Union Health Ministry to file their reply on the...
Health Bulletin 3/October/2022 Roshni Dhar3 Oct 2022 5:24 PM ISTHere are the top health news for the day:NMC seeks report on suicides by medicos, directs institutes to submit data Taking cognizance of the...
Kerala HC directs Health Ministry, DoP to reply on unaffordability of patented cancer drug Ribociclib Farhat Nasim2 Oct 2022 4:00 PM ISTThiruvananthapuram: The Kerala High Court has directed the Department of Pharmaceuticals (DoP) and a competent officer of Union Health Ministry to...
Novartis Kisqali adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer Ruchika Sharma11 Sept 2022 3:18 PM ISTBasel: Pharma major, Novartis, has announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program,...
